Physician profile
Timothi J Beth
NPI 1629083431
$3,956.59
in general payments reported to CMS, 2019-2025
27 companies · $598 in 2025
The $598 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2021: $11.63 · 2022: $535 · 2023: $1,349 · 2024: $1,002 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,948.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $891.21 | 2022-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $672.43 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $525.02 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $209.26 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $199.97 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $183.41 | 2022-2025 | Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $176.06 | 2019-2025 | |
| Abbott Laboratories | $173.99 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $172.34 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.18 | 2019-2023 | Jardiance, Tradjenta |
| Exact Sciences Corporation | $104.67 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $93.87 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $77.70 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $66.41 | 2019-2023 | Veozah |
| Glaxosmithkline, LLC. | $42.23 | 2025 | Bexsero, Arexvy, Shingrix |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $31.49 | 2022 | |
| Digital Diagnostics INC. | $28.61 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.18 | 2019 | |
| Globus Medical, INC. | $22.69 | 2025 | Senza |
| Irhythm Technologies, INC. | $22.47 | 2019 | |
| Inspire Medical Systems, INC. | $21.42 | 2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $20.31 | 2019 | |
| Dexcom, INC. | $20.00 | 2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $17.87 | 2023 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $17.83 | 2023 | Eliquis |
| Sunovion Pharmaceuticals INC. | $15.30 | 2019 | |
| Mylan Specialty L.P. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothi Beth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.